Standard Operating Procedure for Stability Testing during Product Development in Sterile Injectable Manufacturing

Department	Sterile Injectable Manufacturing
SOP No.	SOP/SIM/017/2025
Supersedes	SOP/SIM/017/2022
Page No.	Page 1 of 14
Issue Date	18/06/2025
Effective Date	20/06/2025
Review Date	18/06/2026

1. Purpose

To define a systematic and compliant approach for conducting stability studies of sterile injectable products during the development phase to establish shelf life, support formulation development, and determine storage conditions.

2. Scope

This SOP is applicable to R&D, QA, and QC personnel involved in planning, executing, and analyzing stability studies for new and reformulated sterile injectable products during development.

3. Responsibilities

• R&D Formulation Team: Identifies formulation to be subjected to stability study and finalizes protocol.
• QC Stability Team: Conducts testing at scheduled intervals and maintains data integrity.
• QA Department: Reviews stability protocols and ensures GMP and ICH Q1A compliance.
• Stability Coordinator: Ensures timely initiation and sampling, maintains stability chambers.

4. Accountability

The Head of Quality Assurance is accountable for compliance to the stability testing procedures and for the review and approval of all related protocols and reports.

5. Procedure

5.1 Preparation of Stability Protocol

1. Formulation scientist drafts a protocol containing:
   • Product name and code
   • Batch details and packaging
   • Storage conditions as per ICH guidelines
   • Test parameters and frequency
2. Protocol is reviewed and approved by QA (Annexure-1).

5.2 Sample Preparation and Labeling

1. Prepare lab-scale/pilot batches using GMP practices.
2. Label vials/syringes with:
   • Study code
   • Storage condition
   • Sampling point (T0, T1, etc.)

5.3 Storage Conditions

1. Place samples in qualified stability chambers with:
   • 25°C ± 2°C / 60% RH ± 5% RH
   • 30°C ± 2°C / 65% RH ± 5% RH
   • 40°C ± 2°C / 75% RH ± 5% RH (accelerated)
   • 2–8°C (for refrigerated products)
2. Chambers must be monitored continuously and deviations documented.

5.4 Testing Schedule

1. Testing intervals include:
   • Accelerated: 0, 1, 2, 3, and 6 months
   • Long-term: 0, 3, 6, 9, 12, 18, and 24 months
2. QC performs testing as per approved protocol and SOPs.

5.5 Parameters to be Tested

1. Appearance (clarity, color, precipitate)
2. pH, osmolarity, and viscosity
3. Assay and degradation products (HPLC)
4. Sterility (initial and long-term)
5. Particulate matter (as per USP <788>)
6. Container closure integrity

5.6 Data Recording and Review

1. Enter test results in the Stability Data Sheet (Annexure-2).
2. Compare with acceptance criteria defined in the protocol.
3. Investigate any out-of-specification (OOS) or out-of-trend (OOT) results per SOP.

5.7 Stability Summary Report

1. Prepare a comprehensive report at the end of the study or after a significant milestone.
2. Include:
   • Trend charts
   • Storage conditions and deviations
   • Conclusion on shelf life and storage
3. Submit for QA approval (Annexure-3).

6. Abbreviations

• SOP: Standard Operating Procedure
• QC: Quality Control
• QA: Quality Assurance
• RH: Relative Humidity
• ICH: International Council for Harmonisation
• OOS: Out of Specification
• OOT: Out of Trend

7. Documents

1. Stability Protocol Template – Annexure-1
2. Stability Data Sheet – Annexure-2
3. Stability Summary Report – Annexure-3

8. References

• ICH Q1A(R2): Stability Testing of New Drug Substances and Products
• ICH Q1E: Evaluation for Stability Data
• WHO Technical Report Series No. 1010

9. SOP Version

Version: 2.0

10. Approval Section

	Prepared By	Checked By	Approved By
Signature
Date
Name
Designation	Stability Scientist	QA Reviewer	QA Head
Department	R&D	Quality Assurance	Quality Assurance

11. Annexures

Annexure-1: Stability Protocol Template

Product Name	Injection-X
Batch No.	DEV-STB-001
Storage Condition	25°C / 60% RH
Duration	12 Months
Prepared By	Rajesh Kumar

Annexure-2: Stability Data Sheet

Time Point	Appearance	Assay (%)	Degradation (%)	pH	Performed By
0 Month	Clear	99.8	0.1	6.9	Sunita Reddy
3 Month	Clear	99.2	0.3	6.8	Sunita Reddy

Annexure-3: Stability Summary Report

Report Title	Stability Study Report for Injection-X
Period Covered	0–6 Months
Conclusion	Product stable at all tested conditions
Prepared By	Arvind Joshi
Approved By	QA Head

Revision History

Revision Date	Revision No.	Details	Reason	Approved By
10/01/2022	1.0	Initial SOP release	New protocol development	QA Manager
18/06/2025	2.0	Revised ICH Q1A(R2) implementation	ICH updates	QA Manager